MRNA Nov 2024 125.000 put
| Previous close | 45.80 |
| Open | 45.80 |
| Bid | 54.15 |
| Ask | 55.95 |
| Strike | 125.00 |
| Expiry date | 2024-11-15 |
| Day's range | 45.80 - 45.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 374 |
- Yahoo Finance Video
Moderna stock plunges after slashing R&D budget
Shares of Moderna (MRNA) are declining in Thursday's pre-market trading session following the company's announcement of significant cuts to its research and development budget. This decision comes as demand for its COVID-19 vaccines continues to wane. The biotech company plans to reduce its R&D spending by $1.1 billion and scale back its drug pipeline, aiming to release 10 new products in the coming years. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
Investor's Business DailyIndexes Rally As Nvidia Clears Important Level; Cathie Wood Unloads AI Leader After 100% Gain (Live Coverage)
Indexes were mixed in the stock market today after inflation showed signs of easing. Nvidia cleared a key level after analysts made it a top pick.
Barrons.comModerna Stock Heads to Its Lowest Since 2020. What Is Spooking the Market.
Moderna stock was slumping Thursday after it announced a major pullback in its research and development efforts, as the drugmaker seeks to stretch its cash to cover an extended period of losses. Shares were down 18% to $65.47, headed for what would be their lowest close since September 2020, according to Dow Jones Market Data. The company said it plans to cut research and development spending by 20% beginning in 2025, pausing a number of drug programs and discontinuing others.
